Brooks Automation, now renamed Azenta, is a life sciences company that specializes in the cold-storage and management of biological samples for drug research. It generated $590 million in revenue last year following the sale of its legacy semiconductor business. After a rocky transition into a pure-play life sciences firm, the company is currently navigating a difficult demand environment while attempting to fix execution issues in its core sequencing and storage units.
The investment thesis on Azenta is that it owns a critical infrastructure bottleneck in the life sciences industry, as researchers increasingly require massive, reliable cold-storage for genomic data. More specifically, four things need to be true:
We view Azenta as a high-potential turnaround story that is currently being penalized for a messy transition and lowered guidance. If management can prove it has fixed its internal sales execution issues, the company sits in a strong position to benefit from the long-term trend toward personalized medicine.
The stock price of Brooks Automation, now called Azenta, has essentially gone nowhere over the past five years. The company went through a difficult period after it sold off its main chip business to focus entirely on storing biological samples for drug research. It is currently stuck while trying to fix problems with its core storage and lab services.
What does it do?
Azenta earns money by providing automated storage and analysis services for biological samples used in drug development. It serves as the "cold chain" backbone for life sciences, renting out space in its massive sample repositories and selling the specialized robotics and cryopreservation systems that labs use on-site. The company also operates a large genomics business called Multiomics, where it charges researchers to sequence and synthesize DNA, providing the data needed to understand how diseases function and how drugs might treat them.
Where does revenue come from?
The business is split between physical storage products and high-touch lab services. Revenue is divided into two main segments: Sample Management Solutions (56% of revenue), which includes the sale of automated freezers and consumables, and Multiomics (44% of revenue), which covers genomic sequencing and gene synthesis. Geographically, the company relies heavily on the North American market, though it maintains a global footprint across Europe and the Asia Pacific region.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Azenta serves over 1,000 global customers, including all of the top 20 pharmaceutical companies and leading academic institutions. The customer base is split between large enterprise pharmaceutical firms that use Azenta for long-term sample storage and smaller biotech firms that outsource their sequencing needs. While the company does not disclose exact merchant or consumer counts in its quarterly releases, its reach is defined by its deep integration into the R&D pipelines of the world's largest healthcare organizations.
What gives it staying power?
Azenta has high staying power because biological samples are often stored for decades, creating incredibly high switching costs. Once a pharmaceutical giant has thousands of irreplaceable patient samples stored in an Azenta-managed facility or system, moving them is physically risky and logistically complex, leading to a very steady stream of recurring storage fees.
Where is it headed?
The company is focusing entirely on its Azenta Business System to drive better commercial execution and operational efficiency. Management is currently consolidating its footprint and trying to turn around the Multiomics segment, which has recently struggled with sales productivity. The long-term goal is to become the primary platform where all biological samples are stored, managed, and analyzed throughout the entire drug discovery lifecycle.
Revenue growth has stalled as the company faces a more cautious demand environment in North America. While reported revenue grew 1% to $145 million in the most recent quarter, organic revenue actually declined 3%, showing that the core business is currently shrinking.
Cash generation is positive but significantly lower than historical levels due to heavy reinvestment and operational gaps. The company generated $5 million in free cash flow this past quarter, representing a modest 3.4% margin, which trails management's long-term targets as they struggle with fixed-cost absorption.
The balance sheet is the company's greatest financial strength, characterized by a massive net cash position. With $565 million in cash and marketable securities against almost no debt, Azenta has the liquidity to withstand a prolonged industry downturn or fund strategic acquisitions.
Azenta is a business in a difficult transition whose massive cash pile currently masks poor operating profitability.
The Sample Repository and Consumables business continues to show resilience with 2% growth despite the broader slowdown. This recurring revenue stream provides a floor for the business while more volatile equipment sales and sequencing services underperform.
The failed closing of the B Medical Systems sale for $63 million is a major red flag for management's divestiture strategy. If the buyer, Thelema, cannot secure financing, Azenta will be stuck with a non-core asset that continues to weigh on overall earnings and focus.
The life sciences sample management and genomics market is roughly $15 billion today and is expected to reach $22 billion by 2029 as clinical trials become more data-intensive. Pricing power is structural in sample storage due to the irreplaceable nature of biological assets, but it is a race on price in the sequencing market. Azenta is a leading niche player that owns the "cold chain," but it faces intense competition from diversified giants. Boldly stated, the industry is shifting from simple storage to integrated data management.
The competitive dynamic in life sciences services is becoming increasingly bifurcated between high-end specialized storage and commoditized genomic sequencing. While barriers to entry in automated cryogenics are high due to engineering complexity, the genomics space is seeing significant pricing pressure. Long-term pricing power depends on whether Azenta can bundle its storage and analysis into a single must-have platform.
Thermo Fisher is the primary threat, as it can bundle storage into its massive existing laboratory supply contracts. Hamilton Company competes fiercely in the high-end automated storage niche, often winning on engineering reputation. Thermo Fisher remains the most dangerous threat because of its ability to underprice Azenta on integrated lab services.
Azenta is currently under pressure and likely losing share in its sequencing business. The recent goodwill impairment of $149 million suggests that past acquisitions are not performing as expected. Azenta is holding ground in storage but losing momentum in genomics.
The primary source of protection is high switching costs found in the Sample Management segment. Pharmaceutical companies cannot easily move thousands of delicate, frozen samples once they are logged into Azenta’s proprietary software and physical repositories. The physical risk of thawing samples during a move creates a natural lock-in for Azenta.
The numbers tell a story of a business with a structural edge that is being poorly managed. While gross margins of 44% are healthy, the negative ROIC of -0.7% shows that the company is not yet efficient at turning its assets into profit. Current margins prove the business model is solid, but the returns on capital show a lack of operational discipline.
The moat is currently stable in storage but eroding in the sequencing business due to commoditization. The long-term verdict depends on whether management can successfully bundle its services to raise switching costs further.
Revised FY2026 guidance down after failing to meet internal sales targets.
$250M share buyback authorized, but $149M goodwill impairment recorded.
CEO John Marotta holds a stake, but recent performance has lagged incentives.
Capital Allocation Track Record
Management is currently in a "show me" period after execution gaps in North America led to a significant guidance cut. CEO John Marotta has been honest about the company's internal failures, specifically in the Multiomics segment, and is pivoting to a "productivity-first" model. While the massive cash pile provides a safety net, the $149 million impairment charge indicates that management overpaid for past growth, and they must now prove they can grow organically without expensive, dilutive acquisitions.
The primary governance risk is the company's struggle to complete its planned divestitures, which keeps the business more complex than it needs to be. The failed closing of the B Medical Systems sale suggests a lack of deal-closing rigor or a worsening market for the company's non-core assets. If Marotta cannot streamline the portfolio and hit the new 2029 targets, shareholder pressure for a more drastic leadership change or a full sale of the company is likely to increase.
We expect revenue to grow from $0.6B in FY2026 to $0.8B in FY2031 (~5% CAGR), with EPS growing from $0.45 to $1.74 (~31% CAGR). Revenue growth is driven by the increasing global demand for automated cryopreservation and sample management in genomic research. Operating margins expand as the company leverages its specialized cold-storage infrastructure across a larger volume of high-value biological samples. EPS grows faster than revenue because the business is transitioning Operating margin expected to reach ~22% by FY2031.
Automated cryopreservation becomes the standard for cell and gene therapy. If biotech firms shift toward larger-scale personalized medicine, demand for Azenta's specialized automated storage systems will grow exponentially.
Multiomics productivity fixes drive high-margin sequencing revenue recovery. Successful implementation of the Azenta Business System could restore sequencing margins and return the segment to organic growth.
Massive cash pile funds a transformational, accretive acquisition. With $565 million in net cash, Azenta can acquire a high-growth laboratory service provider to fill gaps in its portfolio.
Prolonged R&D spending freeze by major pharmaceutical customers. If large pharma companies continue to pull back on North American spending, Azenta's high-end equipment sales will continue to stall.
Continued commoditization of genomic sequencing erodes Multiomics margins. If low-cost sequencing rivals continue to gain share, Azenta's genomics business may never reach its 2029 profitability targets.
B Medical Systems divestiture remains stalled or fails completely. Failure to sell B Medical would force Azenta to keep a non-core, lower-margin business on the books, distracting management focus.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach based on FY+1 (FY2027) earnings. This framework fits Azenta because the company is currently in a loss-making turnaround phase, and forward earnings capture the expected recovery in genomic services margins better than trailing GAAP losses. Price-to-earnings is the standard for mature life science tools companies, allowing for a clear comparison against industry peers despite current operational noise.
An FY2027 EPS of $0.61 multiplied by a 51x "recovery" multiple results in a fair value of $31 per share. This 51x multiple sits well above mature life science peers like Thermo Fisher (25x) and Danaher (26x) to account for the depressed earnings base during the early stages of the turnaround; however, this aggressive multiple still exposes a massive disconnect with the current $113.10 market price. The $0.61 EPS basis is taken directly from the deterministic projection engine, reflecting a successful transition back to adjusted profitability.
A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $31, perfectly aligning with our multiple-based approach. Using a 10% discount rate and the deterministic EPS path ($0.45 to $1.74), the DCF confirms that the current market price of $113.10 is factoring in nearly 44% annual growth, which is mathematically incompatible with the company's 3.5% organic reality. The two methods strongly agree that the stock is fundamentally overvalued by more than 70%.
We're assuming Azenta hits its guidance for 300 basis points of adjusted EBITDA margin expansion by the end of FY2026. Management cited cost discipline and a robust order funnel in the latest results as primary drivers for this expansion, which is essential to move from GAAP losses to the $0.61 adjusted EPS projected for next year.
We're assuming the genomic services turnaround is a multi-year effort that will not contribute significantly to growth until late FY2027. The current outlook highlights significant internal sales execution hurdles, meaning the company will rely almost entirely on its core automated storage niche to carry the valuation in the near term.
The biggest risk is the market's continued mispricing of Azenta as a high-growth AI semiconductor play rather than a slow-growth life sciences business. This over-valuation creates massive air pocket risk, where a single quarter of missed guidance could compress the multiple from its current extreme levels toward the peer average of 25x, knocking nearly $80 off the per-share price. Watch for any shift in management's organic growth guidance below 3%.
Bear case ($22): Organic revenue growth remains stalled below 2% through FY2027 as genomic services turnaround fails; or Adjusted EBITDA margins fail to expand, forcing a multiple de-rating to 20x on lower earnings.
Bull case ($45): Genomic services turnaround accelerates with margins hitting 15% by late FY2027; or Market awards a "quality leader" multiple of 45x as company achieves mid-teens organic growth.
Clearthesis wrote this report from 29 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.